Details for Patent: 10,457,666

Which drugs does patent 10,457,666 protect, and when does it expire?

Patent 10,457,666 protects LONSURF and is included in one NDA.

This patent has fifty-one patent family members in thirty countries.

Summary for Patent: 10,457,666

Title:	Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Abstract:	Crystal Form I of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting powder X-ray peaks at two or more angles selected from the group consisting of 11.6°, 17.2°, 17.8°, 23.3°, 27.1°, and 29.3° as a diffraction angle (2θ±0.2°).
Inventor(s):	Hideki Kazuno, Tomonobu MUTSUMI
Assignee:	Taiho Pharmaceutical Co Ltd
Application Number:	US15/969,434
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,457,666
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 10,457,666

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Taiho Oncology	LONSURF	tipiracil hydrochloride; trifluridine	TABLET;ORAL	207981-001	Sep 22, 2015	AB	RX	Yes	No			Y	Y
Taiho Oncology	LONSURF	tipiracil hydrochloride; trifluridine	TABLET;ORAL	207981-002	Sep 22, 2015	AB	RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 10,457,666

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2013-126567	Jun 17, 2013

International Family Members for US Patent 10,457,666

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014282281
Australia	2017208215
Australia	2018219967